share_log

Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K/A：外国发行人报告（业绩相关）
美股sec公告 ·  06/27 12:43
Moomoo AI 已提取核心信息
Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.
Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.
临床阶段生物制药公司Cybin Inc.已提交2024年6月SEC修订报告，纠正了其原始6-K表单中的无意中参考内容，并更新了展示指数中一项新闻发布的日期。该公司专注于开发以致幻剂为基础的精神健康疾病治疗方法，在2024财年取得了显著进展。Cybin Inc.为CYB003获得了FDA突破性治疗设计，这是针对重度抑郁症的一种褐色素类似物，并完成了面向2024年夏季的一份3期多中心研究的选址工作。该公司还启动了一个针对广泛性焦虑症的CYB004的2期研究。财务方面，Cybin Inc.报告了截至2024年3月31日的现金总额为2.09亿加元，并完成了1.5亿美元超额认购的定向增发。尽管取得了这些进展，该公司在2024年度的净亏损增加了7800万加元，而上年为4700万加元。该公司的CEO Doug Drysdale对即将到来的3期研究和他们的治疗方法对精神健康疾病的潜在影响表示乐观。
临床阶段生物制药公司Cybin Inc.已提交2024年6月SEC修订报告，纠正了其原始6-K表单中的无意中参考内容，并更新了展示指数中一项新闻发布的日期。该公司专注于开发以致幻剂为基础的精神健康疾病治疗方法，在2024财年取得了显著进展。Cybin Inc.为CYB003获得了FDA突破性治疗设计，这是针对重度抑郁症的一种褐色素类似物，并完成了面向2024年夏季的一份3期多中心研究的选址工作。该公司还启动了一个针对广泛性焦虑症的CYB004的2期研究。财务方面，Cybin Inc.报告了截至2024年3月31日的现金总额为2.09亿加元，并完成了1.5亿美元超额认购的定向增发。尽管取得了这些进展，该公司在2024年度的净亏损增加了7800万加元，而上年为4700万加元。该公司的CEO Doug Drysdale对即将到来的3期研究和他们的治疗方法对精神健康疾病的潜在影响表示乐观。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息